“Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program”, J of Skin, vol. 7, no. 2, p. s118, Mar. 2023, doi: 10.25251/skin.7.supp.118.